Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma-Reference-Cited by-同舟云学术

Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma

Published:2017-04-19 Issue:1 Volume:7 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Goričar Katja,Kovač Viljem,Dolžan Vita

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/srep46537.pdf

Reference47 articles.

1. Bonanno, L. Predictive models for customizing chemotherapy in advanced non-small cell lung cancer (NSCLC). Transl. Lung Cancer Res. 2, 160–171 (2013).

2. Sim, S. C., Kacevska, M. & Ingelman-Sundberg, M. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenomics J 13, 1–11 (2013).

3. Kovac, V., Zwitter, M. & Zagar, T. Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients. Radiol. Oncol. 46, 136–144 (2012).

4. Damhuis, R. A., Schroten, C. & Burgers, J. A. Population-based survival for malignant mesothelioma after introduction of novel chemotherapy. Eur. Respir. J. 40, 185–189 (2012).

5. Vogelzang, N. J. et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21, 2636–2644 (2003).

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Systematic Review of Polygenic Models for Predicting Drug Outcomes;Journal of Personalized Medicine;2022-08-27

2. Pharmacogenetic Profiling in High-Risk Soft Tissue Sarcomas Treated with Neoadjuvant Chemotherapy;Journal of Personalized Medicine;2022-04-11

3. Dynamic contrast-enhanced MRI in malignant pleural mesothelioma: prediction of outcome based on DCE-MRI measurements in patients undergoing cytotoxic chemotherapy;BMC Cancer;2022-02-20

4. Extracellular Vesicle Enriched miR-625-3p Is Associated with Survival of Malignant Mesothelioma Patients;Journal of Personalized Medicine;2021-10-09

5. Current Mesothelioma Treatment and Future Perspectives;Mesothelioma;2020-11-11